alexa Treatment for Neuromyelitis Optica

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Treatment for Neuromyelitis Optica

Neuromyelitis Optica (NMO) is a rare relapsing autoimmune disorder that preferentially causes inflammation in the optic nerve and spinal cord. It is characterized by longitudinally extensive transverse myelitis (LETM, myelitis which is 3 vertebral segments in length or greater), which can leave one quite debilitated at presentation, and unilateral or bilateral optic neuritis. It was once thought of as a variant of Multiple Sclerosis (MS), and is still oftentimes misdiagnosed as MS. However, several factors differentiate it from MS: 1) it does not often involve the brain, especially early in the disease, 2) the severity of attacks is more robust as compared to MS, and 3) the pathophysiology differs from MS – whereas MS is thought to largely be a T-cell mediated disease, NMO is mediated by anti-aquaporin 4 antibodies. Blood testing includes an anti-aquaporin-4 antibody (NMO-IgG) test, which is highly specific (>99%) and its sensitivity ranges from 48-72%, depending on the assay used. Treatment for this disease involves acute management with therapies, including IV methylprednisolone and plasma exchange (PLEX), and prevention of future attacks with immunosuppressants, including mycophenolate mofetil or rituximab, and aggressive rehabilitation

https://www.omicsgroup.org/journals/interleukin6-receptor-a-novel-therapeutic-target-for-neuromyelitis-optica-2168-975X-1000e119.php?aid=55945

 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
 
adwords